131 related articles for article (PubMed ID: 8220401)
1. Sample size determination using an interim analysis.
Bristol DR
J Biopharm Stat; 1993 Sep; 3(2):159-66. PubMed ID: 8220401
[TBL] [Abstract][Full Text] [Related]
2. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
3. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
4. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
5. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
6. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
Schäfer H; Müller HH
Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
[TBL] [Abstract][Full Text] [Related]
7. Self-designing trial combined with classical group sequential monitoring.
Yin G; Shen Y
J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
[TBL] [Abstract][Full Text] [Related]
8. [Analysis and importance of statistical power and sample size in empirical scientific research].
Klimek KM
Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
[TBL] [Abstract][Full Text] [Related]
9. A seamless phase II/III design with sample-size re-estimation.
Bischoff W; Miller F
J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
[TBL] [Abstract][Full Text] [Related]
10. Adaptive statistical analysis following sample size modification based on interim review of effect size.
Hung HM; Cui L; Wang SJ; Lawrence J
J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173
[TBL] [Abstract][Full Text] [Related]
11. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
12. Optimal timing for interim analyses in clinical trials.
Togo K; Iwasaki M
J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
[TBL] [Abstract][Full Text] [Related]
13. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
14. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
15. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
Dunnigan K; King DW
Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
[TBL] [Abstract][Full Text] [Related]
16. Sample size re-estimation for adaptive sequential design in clinical trials.
Gao P; Ware JH; Mehta C
J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a two-stage and three-stage interim-analysis procedure.
Overall JE; Atlas RS
Psychol Rep; 1992 Aug; 71(1):3-14. PubMed ID: 1529071
[TBL] [Abstract][Full Text] [Related]
18. A note on the power of Fisher's least significant difference procedure.
Meier U
Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
[TBL] [Abstract][Full Text] [Related]
19. [Interim analysis in clinical trials: a methodological guide].
Muñoz Navarro SR; Bangdiwala SI
Rev Med Chil; 2000 Aug; 128(8):935-41. PubMed ID: 11129556
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of experiments with adaptive interim analyses.
Bauer P; Köhne K
Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
